Paper of interest comparing cardiomyopathy risk following treatment with doxorubicin, daunorubicin or mitoxantrone.
The following paper was brought to our attention. As it does not have any Canadian authors it would not have been featured in your January Sosido Digests.
Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.Feijen EAM, Leisenring WM, Stratton KL, Ness KK, van der Pal HJH, van Dalen EC, Armstrong GT, Aune GJ, Green DM, Hudson MM, Loonen J, Oeffinger KC, Robison LL, Yasui Y, Kremer LCM, Chow EJ.JAMA Oncol. 2019 Jan 31. doi: 10.1001/jamaoncol.2018.6634. [Epub ahead of print]